These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 17559141

  • 1. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
    Cancer; 2007 Jul 15; 110(2):345-52. PubMed ID: 17559141
    [Abstract] [Full Text] [Related]

  • 2. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 15; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 3. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U.
    Leuk Res; 2009 Sep 15; 33(9):1189-93. PubMed ID: 19428106
    [Abstract] [Full Text] [Related]

  • 4. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J.
    Cancer; 2005 May 15; 103(10):2082-90. PubMed ID: 15830348
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.
    Cancer; 2006 Mar 01; 106(5):1099-109. PubMed ID: 16435387
    [Abstract] [Full Text] [Related]

  • 7. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M.
    Int J Hematol; 2000 Aug 01; 72(2):139-50. PubMed ID: 11039661
    [Abstract] [Full Text] [Related]

  • 8. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar 01; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.
    Ann Hematol; 2005 Dec 01; 84 Suppl 1():61-6. PubMed ID: 16270213
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
    Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E, Finnish Leukaemia Group.
    Eur J Haematol; 2007 Jun 01; 78(6):477-86. PubMed ID: 17391337
    [Abstract] [Full Text] [Related]

  • 13. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 01; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 14. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N, Acute Leukemia French Association, Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS), Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup.
    J Clin Oncol; 2009 Oct 01; 27(28):4747-53. PubMed ID: 19720919
    [Abstract] [Full Text] [Related]

  • 15. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T.
    Cancer; 2007 Mar 01; 109(5):907-14. PubMed ID: 17285599
    [Abstract] [Full Text] [Related]

  • 16. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
    Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D, Puig B, Gastaut JA, Maraninchi D, Vey N.
    Cancer; 2007 Apr 01; 109(7):1376-83. PubMed ID: 17326052
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 01; 26(12):705-9. PubMed ID: 16620570
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.